Paranthropus Should Not Be Called Nutcracker Man, New Study Says

A photo of a Neanderthal man ancestor's reconstruction, displayed in a 2004 show at the Prehistoric Museum in Germany. (AFP)
A photo of a Neanderthal man ancestor's reconstruction, displayed in a 2004 show at the Prehistoric Museum in Germany. (AFP)
TT

Paranthropus Should Not Be Called Nutcracker Man, New Study Says

A photo of a Neanderthal man ancestor's reconstruction, displayed in a 2004 show at the Prehistoric Museum in Germany. (AFP)
A photo of a Neanderthal man ancestor's reconstruction, displayed in a 2004 show at the Prehistoric Museum in Germany. (AFP)

A new study published in the latest issue of the Journal of Human Evolution, found that the genus Paranthropus, one of the prehistoric humans species, does not deserve the Nutcracker Man title.

The Paranthropus group stands out in this family tree because of their massive back teeth, several times the size of ours, and their extremely thick enamel (the outer-most layer of our teeth). But the new study that examined Paranthropus' fossilized teeth and enamel found new evidence on its diet.

Researchers Ian Towle and Carolina Loch from the University of Otago, New Zealand, in collaboration with researcher Joel Irish from the University of Liverpool's School of Biology and Environmental Science, found that Paranthropus had very low rates of enamel chipping (a common type of tooth fracture), comparable to living primates such as gorillas and chimpanzees. This supports other recent research about the diet of this group and should finally put to rest the nutcracker hypothesis.

"Our understanding of diet and behavior during human evolution has changed markedly over the last decades — partly due to new technologies but also because of some spectacular fossil discoveries, mainly teeth," the researchers said in a report posted on The Conversation website, on July 24.

They explained that teeth are by far the most abundant resource because they survive fossilization better than bones. This is a fortunate circumstance because teeth also offer other information that helps us to reconstruct the environment of our fossil ancestors and relatives. We can glean a lot of information from the microscopic scratches created by foods scraping along the tooth surface during chewing, the tiny particles preserved in dental plaque and the chemical composition of the teeth themselves, they added.

Before such techniques were developed and refined, researchers relied on looking at the overall shape and size of teeth, as well as wear and chipping visible with the naked eye. Small sample sizes and a lack of comparative material hampered these studies, but they provided some bold claims about the diet of our fossil ancestors, including its reliance on hard foods.

"In our recent research, we have studied a broad range of living primates and compared that information with data on fossil species. The results were surprising, with our species Homo sapiens and fossil relatives in our genus commonly showing high rates of chipping, similar to living primates that eat hard foods habitually," they concluded.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”